【佳學(xué)基因檢測(cè)】飛行質(zhì)譜基因檢測(cè)發(fā)現(xiàn)ADRA2A有突變，嚴(yán)重嗎？

基因檢測(cè)的序列名稱：

ADRA2A

人體基因序列變化與疾病表征數(shù)據(jù)庫中的基因代碼：

150

人體基因序列數(shù)據(jù)庫中國(guó)際交流名稱全稱

adrenoceptor alpha 2A

中國(guó)數(shù)據(jù)庫中基因全稱：腎上腺素受體2A基因檢測(cè)報(bào)告英文版基因簡(jiǎn)介

Alpha-2-adrenergic receptors are members of the G protein-coupled receptor superfamily. They include 3 highly homologous subtypes: alpha2A, alpha2B, and alpha2C. These receptors have a critical role in regulating neurotransmitter release from sympathetic nerves and from adrenergic neurons in the central nervous system. Studies in mouse revealed that both the alpha2A and alpha2C subtypes were required for normal presynaptic control of transmitter release from sympathetic nerves in the heart and from central noradrenergic neurons; the alpha2A subtype inhibited transmitter release at high stimulation frequencies, whereas the alpha2C subtype modulated neurotransmission at lower levels of nerve activity. This gene encodes alpha2A subtype and it contains no introns in either its coding or untranslated sequences. [provided by RefSeq, Jul 2008]

基因突變所影響的基因信息

Alpha-2-腎上腺素受體是G蛋白偶聯(lián)受體超家族的成員。它們包括3個(gè)高度同源的亞型：alpha2A，alpha2B和alpha2C。這些受體在調(diào)節(jié)交感神經(jīng)和中樞神經(jīng)系統(tǒng)中腎上腺素能神經(jīng)元的神經(jīng)遞質(zhì)釋放中起關(guān)鍵作用。小鼠研究表明，正常的突觸前控制心臟中交感神經(jīng)和中樞去甲腎上腺素能神經(jīng)元的遞質(zhì)釋放需要α2A和α2C亞型。alpha2A亞型在高刺激頻率下抑制了遞質(zhì)的釋放，而alpha2C亞型在較低的神經(jīng)活動(dòng)水平下調(diào)節(jié)了神經(jīng)傳遞。該基因編碼alpha2A亞型，并且在其編碼序列或非翻譯序列中均不含內(nèi)含子。[由Re??

國(guó)際國(guó)內(nèi)該堿基因序列的其他英語文字母簡(jiǎn)稱：

ADRA2, ADRA2R, ADRAR, ALPHA2AAR, ZNF32

基因解碼對(duì)該基因序列在細(xì)胞核中的染色體所給予的編號(hào)：

該基因序列位于人類第10號(hào)染色體上。

基因解碼對(duì)基因序列的正確定位

該基因序列在GRCh37版本中的起始位置坐標(biāo)為：112836790；結(jié)束位置坐標(biāo)為：112840665。該基因序列在GRCh38版本中的起始位置坐標(biāo)為：111077032；結(jié)束位置坐標(biāo)為：111080907。正確的基因信息定位是基因檢測(cè)和對(duì)檢測(cè)結(jié)果進(jìn)行正確解讀的關(guān)鍵。

佳學(xué)基因解碼對(duì)該基因的功能分類：國(guó)際版

G-protein coupled receptors/GPCRs excl olfactory receptors

基因解碼對(duì)該基因的功能分類：中文版

G 蛋白偶聯(lián)受體/GPCR 不包括嗅覺受體

結(jié)構(gòu)與功能基因解碼所揭示的該基因在細(xì)胞內(nèi)發(fā)揮作用的場(chǎng)所（國(guó)際版）：

正在通過基因解碼技術(shù)進(jìn)行收集、查證并編輯，請(qǐng)關(guān)注佳學(xué)基因，獲得及明更新的人類基因序列變化與疾病表征數(shù)據(jù)庫的更新內(nèi)容

結(jié)構(gòu)與功能基因解碼所揭示的該基因發(fā)揮作用的細(xì)胞內(nèi)位置（中文版）：

正在通過基因解碼技術(shù)進(jìn)行收集、查證并編輯，請(qǐng)關(guān)注佳學(xué)基因，獲得及明更新的人類基因序列變化與疾病表征數(shù)據(jù)庫的更新內(nèi)容

該基因序列變化后增加的疾病風(fēng)險(xiǎn)（國(guó)際版）：

Panic Disorder; Fibrosis; Heart Diseases; Hypotension; Cardiomegaly; Mood Disorders; Mental Depression; Alcoholic Intoxication, Chronic; Hypertensive disease; Depressive disorder; Epilepsy; Schizophrenia

如果該基因突變后，風(fēng)險(xiǎn)可能增加的疾病類型（中文版）：

恐慌癥;纖維化；心臟疾病;低血壓;心臟肥大；情緒障礙；精神抑郁癥；酒精中毒慢性；高血壓??；抑郁癥；癲癇;精神分裂癥

GWAS基因檢測(cè)所建立的與該基因的疾病關(guān)聯(lián)（國(guó)際版）：

正在通過基因解碼技術(shù)進(jìn)行收集、查證并編輯，請(qǐng)關(guān)注佳學(xué)基因，獲得及明更新的人類基因序列變化與疾病表征數(shù)據(jù)庫的更新內(nèi)容

GWAS基因檢測(cè)所解碼的該基因突變會(huì)增加風(fēng)險(xiǎn)的疾病種類（中文版）：

正在通過基因解碼技術(shù)進(jìn)行收集、查證并編輯，請(qǐng)關(guān)注佳學(xué)基因，獲得及明更新的人類基因序列變化與疾病表征數(shù)據(jù)庫的更新內(nèi)容

以該基因做靶點(diǎn)的藥物（國(guó)際版）：

Bethanidine (Thioesterase binding);Ziprasidone (Thioesterase binding);Cabergoline (Thioesterase binding);Ropinirole (Thioesterase binding);Dihydroergotamine (Thioesterase binding);Amitriptyline (Thioesterase binding);Olanzapine (Thioesterase binding);Clozapine (Thioesterase binding);Norepinephrine (Thioesterase binding);Mirtazapine (Thioesterase binding);Phenylpropanolamine (Thioesterase binding);Loxapine (Thioesterase binding);Pramipexole (Thioesterase binding);Dipivefrin (Thioesterase binding);Prazosin (Thioesterase binding);Chlorpromazine (Thioesterase binding);Brimonidine (Thioesterase binding);Nortriptyline (Thioesterase binding);Amoxapine (Thioesterase binding);Amoxapine (Thioesterase binding);Clonidine (Thioesterase binding);Lisuride (Thioesterase binding);Guanabenz (Thioesterase binding);Dexmedetomidine (Thioesterase binding);Trazodone (Thioesterase binding);Epinephrine (Thioesterase binding);Phentolamine (Thioesterase binding);Ergotamine (Thioesterase binding);Tizanidine (Thioesterase binding);Apomorphine (Thioesterase binding);Trimipramine (Thioesterase binding);Risperidone (Thioesterase binding);Epinastine (Thioesterase binding);Tolazoline (Thioesterase binding);Fenoldopam (Thioesterase binding);Pseudoephedrine (Thioesterase binding);Benzphetamine (Thioesterase binding);Phenoxybenzamine (Thioesterase binding);Maprotiline (Thioesterase binding);Oxymetazoline (Thioesterase binding);Apraclonidine (Thioesterase binding);Methyldopa (Thioesterase binding);Guanfacine (Thioesterase binding);Ergoloid mesylate (Thioesterase binding);Carvedilol (Thioesterase binding);Doxepin (Thioesterase binding);Nefazodone (Thioesterase binding);Desipramine (Thioesterase binding);Pergolide (Thioesterase binding);Bromocriptine (Thioesterase binding);Quetiapine (Thioesterase binding);Aripiprazole (Thioesterase binding);Paliperidone (Thioesterase binding);Ephedra (Thioesterase binding);Yohimbine (Thioesterase binding);Methotrimeprazine (Thioesterase binding);4-Methoxyamphetamine (Thioesterase binding);Methamphetamine (Thioesterase binding);Propericiazine (Thioesterase binding);Zuclopenthixol (Thioesterase binding);Dronedarone (Thioesterase binding);Lofexidine (Thioesterase binding);Epicept NP-1 (Thioesterase binding);Mianserin (Thioesterase binding);Asenapine (Thioesterase binding);Droxidopa (Thioesterase binding);Flupirtine (Thioesterase binding);Esmirtazapine (Thioesterase binding);Xylometazoline (Thioesterase binding);Naphazoline (Thioesterase binding);Lurasidone (Thioesterase binding);Cirazoline (Thioesterase binding)

針對(duì)該基因所產(chǎn)生的突變，可能有正確效果的藥物（中文版）：

倍他尼定（硫酯酶結(jié)合）；齊拉西酮（硫酯酶結(jié)合）；卡麥角林（硫酯酶結(jié)合）；羅匹尼羅（硫酯酶結(jié)合）；二氫麥角胺（硫酯酶結(jié)合）；阿米替林（硫酯酶結(jié)合）；奧氮平（硫酯酶結(jié)合）；氯氮平（硫酯酶結(jié)合）；去甲腎上腺素（硫酯酶結(jié)合);米氮平(硫酯酶結(jié)合);苯丙醇胺(硫酯酶結(jié)合);洛沙平(硫酯酶結(jié)合);普拉克索(硫酯酶結(jié)合);地匹夫林(硫酯酶結(jié)合);哌唑嗪(硫酯酶結(jié)合);氯丙嗪(硫酯酶結(jié)合);溴莫尼定(硫酯酶結(jié)合) )；去甲替林（硫酯酶結(jié)合）；阿莫沙平（硫酯酶結(jié)合）；阿莫沙平（硫酯酶結(jié)合）；可樂定（硫酯酶結(jié)合）；麥角乙脲（硫酯酶結(jié)合）；瓜那苯（硫酯酶結(jié)合）；右美托咪定（硫酯酶結(jié)合）；曲唑酮（硫酯酶結(jié)合）；腎上腺素（硫酯酶結(jié)合）;酚妥拉明（硫酯酶結(jié)合）;麥角胺（硫酯酶結(jié)合）;替扎尼定（硫酯酶結(jié)合）;阿樸嗎啡（硫酯酶結(jié)合）;曲米帕明（硫酯酶結(jié)合）;利培酮（硫酯酶結(jié)合）;依匹斯汀（硫酯酶結(jié)合）;托拉唑啉（硫酯酶結(jié)合）；非諾多泮（硫酯酶結(jié)合）；偽麻黃堿（硫酯酶結(jié)合）；苯丙胺（硫酯酶結(jié)合）；苯氧苯甲胺（硫酯酶結(jié)合）；馬普替林（硫酯酶結(jié)合）；羥甲唑啉（硫酯酶結(jié)合）；安普樂定（硫酯酶結(jié)合）；甲基多巴（硫酯酶結(jié)合） )；胍法辛（硫酯酶結(jié)合）；麥角環(huán)素甲磺酸鹽（硫酯酶結(jié)合）；卡維地洛（硫酯酶結(jié)合）；多慮平（硫酯酶結(jié)合）；奈法唑酮（硫酯酶結(jié)合）；地昔帕明（硫酯酶結(jié)合）；培高利特（硫酯酶結(jié)合）；溴隱亭（硫酯酶結(jié)合） ;喹硫平（硫酯酶結(jié)合）；阿立哌唑（硫酯酶結(jié)合）；帕利哌酮（硫酯酶結(jié)合）；麻黃（硫酯酶結(jié)合）；育亨賓（硫酯酶結(jié)合）；甲氧美拉嗪（硫酯酶結(jié)合）；4-甲氧苯丙胺（硫酯酶結(jié)合）；甲基苯丙胺（硫酯酶結(jié)合） ;丙哌嗪（硫酯酶結(jié)合）；珠氯噻醇（硫酯酶結(jié)合）；決奈達(dá)?。蝓ッ附Y(jié)合）；洛非西定（硫酯酶結(jié)合）；Epicept NP-1（硫酯酶結(jié)合）；米安色林（硫酯酶結(jié)合）；阿塞那平（硫酯酶結(jié)合）；屈昔多巴（硫酯酶結(jié)合） )；氟吡?。蝓ッ附Y(jié)合）；艾司米氮平（硫酯酶結(jié)合）；賽洛唑啉（硫酯酶結(jié)合）；萘甲唑啉（硫酯酶結(jié)合）；魯拉西酮（硫酯酶結(jié)合）；西拉唑啉（硫酯酶結(jié)合）